AbbVie’s revenue growth forecast for the next few years indicates a strong performance, with some products exceeding expectations. The company’s valuation and dividend program are also appealing. AbbVie has outperformed the market, with shares up by 29% this year. The company projects high single-digit revenue growth through 2029. Skyrizi and Rinvoq’s strong performances contribute to AbbVie’s success.

AbbVie’s financial performance has been solid, with revenue increasing by 8% to $44.5 billion. Adjusted earnings per share declined, but the company remains on track for growth. Skyrizi and Rinvoq are expected to drive sales, while other products like Vraylar and Qulipta will also contribute. Despite challenges like drug price negotiations, AbbVie’s outlook is positive.

AbbVie’s prospects for the next five years look promising, supported by a strong business performance and a robust pipeline. The company’s shares are reasonably valued compared to the sector average and offer a competitive dividend program. With a history of annual dividend raises and solid operations, AbbVie is a strong buy for 2026.

Read more at Yahoo Finance: Is AbbVie a Buy, Sell, or Hold in 2026?